Anika Therapeutics Inc. $ANIK, a global integrated orthopedic medicines company, focused on therapeutics based on its proprietary hyaluronic acid (HA) technology, reported its fiscal third quarter results on Wednesday. For the quarter, EPS was $0.59, beating estimates by $0.12. Revenue was $25.8 million, a 9% increase Y-o-Y; but missing forecast by $0.8 million. “We continued to deliver solid financial results in the third quarter, while expanding globally and advancing our deep and differentiated pipeline to drive sustained growth,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer during the earnings call.
Sangamo Biosciences Inc. $SGMO, reported its fiscal third quarter results on Wednesday and provided an update of recent events and development timelines for its therapeutics programs. For the quarter, EPS was -$0.27, short by $0.02. Revenue was $2.8 million, a drop of 67.3% Y-o-Y, missing estimates by $1.44 million. "The third quarter of 2016 has been a pivotal time for Sangamo, as we worked to focus our efforts and execute on our prioritized therapeutic programs in hemophilia B, hemophilia A, MPS I and MPS II," said Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, during the conference call. "I am pleased to announce that the Phase 1/2 clinical trial for SB-FIX, our in vivo genome editing program for hemophilia B, is open. We are also on track to file an IND application for our AAV cDNA Factor 8 gene therapy program for hemophilia A by the end of this year” added the CEO.
PAREXEL $PRXL reported fiscal quarter 1 results on Wednesday. For the quarter, EPS was $0.76, missing guidance by $0.10. Revenue was $500.9 million, a drop of 2.2% Y-o-Y, and missing guidance by $23.89 million. GAAP diluted earnings per share of $0.75, up 66.7%; Gross new business of $930 million. Company guides to GAAP EPS of $3.55-$3.89 and adjusted EPS of $3.71-$4.05 for Fiscal Year 2017. The Board approved new $200 million share repurchase program.